Diampa Lt Tablets 25mg+5mg

Medicine Name: Diampa Lt Tablets 25mg+5mg

📋 Diampa LT Tablets – Product Specification
________________________________________
💊 Requires Prescription:
Yes
________________________________________
🧪 Generics:
Empagliflozin + Linagliptin
________________________________________
🔍 Used For:
Type 2 Diabetes Mellitus
________________________________________
⚙️ How It Works:
Empagliflozin (SGLT2 Inhibitor):
•    Blocks sodium-glucose co-transporter 2 (SGLT2) in the kidneys
•    Reduces glucose reabsorption from the renal tubules
•    Increases urinary glucose excretion, lowering blood glucose levels
Linagliptin (DPP-4 Inhibitor):
•    Inhibits the enzyme DPP-4, which degrades incretin hormones (GLP-1 and GIP)
•    Enhances insulin secretion and reduces glucagon levels in a glucose-dependent manner
•    Supports glycemic control by increasing insulin and decreasing hepatic glucose production
________________________________________
📦 Dosage:
Empagliflozin + Linagliptin
(Exact dosage should be prescribed by a healthcare professional.)
________________________________________

⚠️ Side Effects:
•    Common:
o    Urinary tract infections (including pyelonephritis, urosepsis)
o    Genital infections (e.g., vulvovaginitis, balanitis)
o    Nasopharyngitis
o    Hypoglycemia (especially with insulin or sulfonylurea)
o    Increased urination, thirst, rash, pruritus, cough
o    Elevated amylase and lipase levels
•    Uncommon:
o    Hypersensitivity reactions (e.g., urticaria, angioedema)
o    Pancreatitis, volume depletion, dysuria
o    Increases in hematocrit, serum lipids, and creatinine
•    Rare/Not Known:
o    Fournier's gangrene (necrotizing fasciitis of the perineum)
o    Bullous pemphigoid
________________________________________
🔄 Drug Interactions:
•    Diuretics:
May increase risk of volume depletion; monitor renal function and hydration
•    1,5-Anhydroglucitol (1,5-AG) Assay:
Not reliable in patients on SGLT2 inhibitors; use alternative glycemic monitoring
•    Strong P-gp/CYP3A4 Inducers (e.g., Rifampin):
May reduce Linagliptin efficacy — alternative therapies recommended
________________________________________
🩺 Indications:
•    Adjunct to diet and exercise in adults with type 2 diabetes mellitus, when:
o    Monotherapy with either agent is insufficient
o    Metformin and/or sulfonylurea are inadequate
o    Patient is already being treated with free combination of both drugs
•    Empagliflozin also indicated to reduce risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
________________________________________

❌ When Not to Use:
Do not use if the patient has:
•    Hypersensitivity to Empagliflozin, Linagliptin, or excipients
•    Known allergy to SGLT2 inhibitors or DPP-4 inhibitors
________________________________________
⚠️ Precautions:
•    Risk of acute pancreatitis with DPP-4 inhibitors, including Linagliptin
•    Discontinue immediately if pancreatitis is suspected
•    Avoid restarting if confirmed
•    Use caution in patients with history of pancreatitis
________________________________________
🚨 Warnings:
Warning 1:
•    Use caution in patients at risk of hypotension
o    Especially those with CVD, on anti-hypertensives, or age ≥75
Warning 2:
•    Increased risk of lower limb amputations, particularly toes
o    Advise patients on preventative foot care
Warning 3:
•    Risk of urinary tract infections
o    Monitor for symptoms and treat promptly if infection is suspected
________________________________________
🤰 Pregnancy Category:
Always consult your physician before using during pregnancy or breastfeeding.
________________________________________

🏠 Storage:
Yes – Store at room temperature, away from direct light and heat